LS-106

• Description :

  LS-106 is an orally active and potent inhibitor against epidermal growth factor receptor (EGFR) . LS-106 exhibits antitumor activities both in vitro and in vivo. LS-106 inhibits the kinase activities of EGFR19del/T790M/C797S and EGFRL858R/T790M/C797S with IC50 values of 2.4 nmol/L and 3.1 nmol/L, respectively, which is more potent than Osimertinib (HY-15772) . LS-106 induces Apoptosis, suppresses cell proliferation of tumor cells harboring EGFR19del/T790M/C797S and leas to significant tumor regression in a C797S-mutant xenograft model[1].

• UNSPSC :

  12352005

• Target :

  Apoptosis; EGFR

• Type :

  Reference compound

• Related Pathways :

  Apoptosis; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/ls-106.html

• Smiles :

  CP(C1=CC=CC=C1NC2=NC(NC3=CC=C(N4CCC(C)CC4)C(Br)=C3)=NC=C2Cl)(C)=O

• Molecular Formula :

  C24H28BrClN5OP

• Molecular Weight :

  548.84

• References & Citations :

  [1]Liu Y, et al. LS-106, a novel EGFR inhibitor targeting C797S, exhibits antitumor activities both in vitro and in vivo. Cancer Sci. 2022 Feb;113 (2) :709-720.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported